A Salt Substitute Can Lower Sodium—and Still Need a Safety Boundary
Potassium-containing lower-sodium table salt is the subject here, and the question is more demanding than whether it has less sodium on its label. The useful judgment is whether replacing regular table salt with it can lower sodium exposure for a particular adult, without creating an unacceptable potassium risk and without pretending that a table-salt change fixes the whole diet. The evidence points to a qualified answer: this can be a valuable tool, but it is not a universal swap.
That qualification matters because the product sits at the intersection of two familiar health messages. Too much sodium raises blood pressure and contributes to cardiovascular risk. Potassium can support healthier blood-pressure regulation, but excess potassium can become dangerous when the body cannot excrete it effectively. A substitute that replaces part of sodium chloride with potassium chloride therefore changes two exposures at once. Its promise and its boundary come from the same design.
The problem is sodium exposure, not the salt container
Salt is the everyday name for sodium chloride, or NaCl. Sodium is one component of that compound, and it is the component that matters most for the public-health target. People can reduce sodium by using less salt, choosing foods made with less salt, changing recipes, reformulating manufactured products, or replacing some regular salt with a product that contains less sodium. These are related strategies, not interchangeable ones.
The scale of the problem explains why substitutes attract attention. The World Health Organization reports that 1.9 million deaths each year are attributable to high sodium intake in the global burden it cites. It also estimates that mean global sodium intake was 4.3 grams per day in 2019, more than twice its recommended adult limit of less than 2 grams per day. High sodium intake raises blood pressure, and reducing sodium lowers blood pressure and the risks of cardiovascular disease, stroke and coronary heart disease. The objective is therefore not to find a new kind of salt that permits the same total sodium intake. The objective is to reduce sodium exposure.
A table-salt substitute can help only if it changes what people actually consume. Regular table salt is almost entirely sodium chloride. A lower-sodium substitute usually removes some of that sodium chloride and replaces it with another mineral or compound, often potassium chloride, or KCl. If someone uses the substitute in the same quantity and for the same purpose, the sodium delivered by each use may fall. But the product still contains sodium, and using more of it can erase some or all of the intended reduction.
This is why the distinction between discretionary and non-discretionary salt is important. Discretionary salt is what a person adds while cooking or eating. Non-discretionary salt is already present in manufactured food, restaurant meals and other food prepared outside the home. The WHO recommendation for potassium-containing lower-sodium salt substitutes is aimed at discretionary table salt. It does not establish that a shaker substitution addresses sodium hidden in bread, packaged meals, sauces or restaurant food. For someone whose main sodium exposure comes from those sources, changing the table salt may have a smaller effect than the label suggests.
The substitute is thus one instrument inside a larger strategy. WHO continues to place reduction of sodium from both discretionary and non-discretionary sources at the center. A substitute can make one behavior less sodium-intensive; it does not turn that behavior into a complete sodium-reduction plan.
What a lower-sodium salt substitute changes
The simplest way to describe the intervention is as a partial exchange: less NaCl, often more KCl. That description is simple, but it already contains the central trade-off. Lower sodium can help reduce blood pressure. Added potassium may also contribute to blood-pressure lowering. At the same time, potassium is not harmless in unlimited amounts for people whose kidneys or medications interfere with potassium excretion.
The products are not one chemically uniform class. A recent systematic review and network meta-analysis grouped substitutes in three overlapping ways. It looked at the primary ingredients, such as mixtures of NaCl and KCl or mixtures that also contained magnesium, calcium or chitosan. It grouped products by KCl content, distinguishing low, moderate and high potassium ranges. It also grouped them by the amount of NaCl remaining, from reduced-sodium to extremely low-sodium formulations. One mixture can receive several labels at once: a product containing 75% NaCl and 25% KCl is a K-salt, a moderate-potassium substitute and a low-sodium substitute under the review's different classification systems.
Those labels answer different questions. The ingredient label tells us what else is in the mixture. The potassium grouping tells us how much KCl was used. The sodium grouping tells us how much NaCl remains. None of these labels, by itself, tells us how a specific person will respond, how much of the product they will use, or whether the product is safe for them.
The biological pathway is also not a single straight line. With partial replacement, the dietary input can contain less sodium and more potassium. Urinary sodium may fall, and urinary potassium may rise. Blood pressure may then change over time. Taste affects whether people continue using the product, and the food setting affects how much regular salt it actually replaces. A product can have the intended composition yet produce little practical sodium reduction if people dislike its taste, use it alongside the old salt, or get most of their sodium from food they do not prepare.
The sources support a possible contribution from potassium that is independent of simply removing sodium. The newer review discusses evidence suggesting potassium enrichment may contribute substantially to the blood-pressure effect. But its own comparisons did not find a significant difference in blood-pressure reduction between substitute formulations. That is an important restraint. A plausible mechanism does not prove that the product with the most potassium is the best product, and a lower-sodium label does not establish a safe personal dose.
The trade-off can be seen in the measurements. In the WHO evidence review, the average serum potassium increase with lower-sodium salt substitutes was 0.12 mmol/L. The review also found average changes in urinary sodium and potassium, but those results varied considerably among studies. The direction is consistent with the design: less sodium and more potassium can enter the body. The size of the change is not fixed, and a biomarker is not the same thing as a cardiovascular outcome.
The diagram's split is the point: benefit and risk are not separate product features that can be considered one at a time. They are consequences of the same replacement. The answer depends on what the mixture contains, who receives it and where it enters the diet.
Why the swap needs a boundary
The most important boundary is potassium handling. The WHO recommendation is conditional and intended for adults in the general population. It excludes people with kidney impairments and people with other conditions or circumstances that might compromise potassium excretion, including use of potassium-sparing medications or potassium supplements. The concern is not theoretical wordplay. If potassium accumulates in the blood, hyperkalaemia can disrupt the heart's electrical activity and, in severe cases, lead to life-threatening events.
The evidence cannot remove that boundary because the trials that supported the WHO review generally excluded people in whom increased potassium might cause harm. Some also excluded people with diabetes. The newer network analysis likewise says that safety evidence in chronic kidney disease, renal impairment and people using potassium-sparing medications is insufficient for confident conclusions. A finding of no significant increase in adverse events among selected trial participants should not be read as proof of safety for groups who were not adequately represented.
This is a general evidence principle with a concrete consequence. A study can answer, “What happened when selected adults used this substitute instead of regular salt?” It may not answer, “What will happen to every person who buys this product?” The second question includes people with undiagnosed kidney disease, different medication regimens, different dietary patterns and different levels of potassium intake from other foods. The first question cannot silently be expanded into the second.
Life stage creates another clear limit. WHO found too little evidence to draw conclusions for pregnant women and very uncertain evidence for children. Its recommendation therefore does not apply to those groups. A household also cannot treat the issue as purely individual: if a family member is at risk for hyperkalaemia, WHO says lower-sodium salt substitutes should not be used to prepare a shared family meal for that member. These are scope boundaries, not claims that every child or pregnant person will be harmed.
Context creates a less dramatic but equally important boundary. The network review found that substitutes were generally acceptable and did not show a meaningful increase in adverse events or withdrawals compared with regular salt in the studied populations. WHO's contextual review nevertheless identified higher price, limited availability, lack of awareness, bad taste and uncertain perceived benefit as barriers. The newer review also notes that taste and adherence can vary across cultures and food systems. A substitute that works in a setting where most meals are prepared at home may have less reach where most sodium comes from food prepared elsewhere.
There is an equity issue here as well. WHO reports that lower-income or less-educated people were less likely to use lower-sodium substitutes, while the median price was about 1.7 times that of regular salt. Just under half of the LSSS available globally were iodized at the time of the guideline, so public-health use also has to align with national iodization policies. Availability, price and iodization are not distractions from efficacy. They determine who can use the intervention and whether it fits the nutritional infrastructure around salt.
The resulting judgment is deliberately less tidy than “replace salt with low-sodium salt.” Potassium-containing lower-sodium table salt can be a useful option for some adults who are replacing discretionary regular salt, especially within the population and formulation boundaries represented by the evidence. But the same product deserves caution when potassium excretion may be impaired, when relevant medicines or medical conditions are present, when the intended users are children or pregnant women, or when the main sodium sources lie outside the kitchen.
That is the vocabulary needed for the harder questions that follow. A lower-sodium substitute is not simply a milder version of regular salt. It is a change in sodium and potassium exposure whose value depends on composition, physiology, adherence and setting. The next step is to examine what the trials actually show—and to keep the strength of each result matched to the people, outcomes and comparisons that produced it.